Artificial Intelligence-assisted Diagnosis in Ophthalmology (NCT07497815)
Development and Validation of an Artificial Intelligence-assisted Diagnostic System for Ophthalmic Pathologies
🩺 Plain-English Summary (8th-Grade Level)
This is a retrospective, multicenter, observational study designed to develop and validate an artificial intelligence (AI) system capable of detecting and classifying major ophthalmic diseases (glaucoma, cataract, diabetic retinopathy, and other retinal pathologies) in the Costa Rican population. The study will use approximately 15,000 existing medical images from digital archives of two ophthalmic centers in Costa Rica, without active participant recruitment or capture of new images. The primary motivation is that AI systems developed in other countries (primarily Asian, European, or North American populations) do not necessarily perform with the same accuracy when applied to Latin American populations. This study seeks to establish a precedent for the importance of locally validating any medical AI technology before clinical implementation.
Who can join: Review the eligibility criteria below.
Location: Centro Ocular — Heredia, Centro
Age range: 18 Years
🧪 Interventions in This Study
- No interventions (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Centro Ocular — Heredia, Centro
- Asociados de Mácula y Vítreo de Costa Rica — San José, Provincia de San José
📞 Contact the Study Coordinator
Phone: (929) 327-8463
Email: marisse@irisciencetech.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Macular Degeneration
- Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration — Mesa, Arizona
- Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss — Edina, Minnesota
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) — Gilbert, Arizona
- A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT — Dallas, Texas
- Learning Study: Improving Vision in Adults With Macular Degeneration — Waterloo, Ontario
Explore by condition: All Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.